Archer Materials Ltd
Archer Materials Limited is a quantum technology company building advanced semiconductor devices for quantum computing, quantum sensing, and medical diagnostics.
The business
Archer Materials Limited is a quantum technology company building advanced semiconductor devices for quantum computing, quantum sensing, and medical diagnostics. The Company principal activities include technology research and development of the carbon nano onion quantum material (12CQ Project), tunnelling magnetoresistance (TMR) sensor project and graphene-based lab-on-a-chip biosensing chip (biochip) and utilizing semiconductor technology development infrastructure and facilities, research, and development to support technology research and development. The Company is focused on developing its biochip technology, including identifying and developing testing for blood potassium levels, for its first target of hypo- and hyperkalemia detection in chronic kidney disease (CKD) patients. Its biochip marks an inflection point in diagnostics, enabling fast, accurate, and low-cost digital testing.
Share price
Market Statistics
Valuation
Trading Activity
Performance
Latest news
Archer Materials Advances Quantum Machine Learning Fraud Detection Project
Archer Materials' QML fraud detector matches classical models in simulator: 118 frauds flagged, 1 false positive; validated on IQM Garnet with AWS Braket.
Archer Materials Advances Biosensor Prototype Toward Preclinical Validation
Archer Materials advances its Biosensor beta prototype toward preclinical validation, targeting external testing and 2027 clinical trials with IMEC collaboration.
Archer Materials Strengthens Pathway to Wafer-Scale Quantum Device Manufacturing
Archer Materials targets wafer-scale quantum production, aims for a working qubit this year, and moves toward foundry-ready, scalable graphene devices.
Archer Materials Advances Quantum and Biochip Platforms Ahead of Key 2026 Prototypes
Archer Materials advances quantum and biochip prototypes, aiming full qubit device and beta biochip by 2026; debt-free with $10.3m cash.
Looking for charts & signals? See the tab.
Unlock the full research library - free.
Create a free account to access every broker report, CEO interview, IPO alert, and daily market wrap. No credit card. No paywall.